Howard Jacobson, PhD is Chief Behavioral Science Officer at WellStart Health. He is contributing author to Whole, by T. Colin Campbell, PhD, and Proteinaholic, by Garth Davis, MD, and the host of the Plant Yourself Podcast.

As co-founder of WellStart Health, Howard guides clients to adopt and maintain lifestyle and dietary habits in alignment with their health goals and life values. Howard has been coaching high performers since 2001. He sits on the advisory board of the International Coach Certification Alliance and is a certified in Peter Bregman’s QUICC Coaching methodology, BJ Fogg’s Tiny Habits, and Glenn Livingston’s Never Binge Again system. He is a visiting scholar at Duke University’s Institute for Advanced Hindsight. 

Howard lives on an ecological farm in rural North Carolina, where he writes, gardens, plays Ultimate Frisbee, runs ultra marathons, and practices Russian Martial Arts. Howard’s goals include shaking up healthcare, sharing how delicious and joyful a healthy life can be, save the planet, and reintroducing people to their most authentic, bipedal, plant-eating, antifragile, best selves. And maybe someday not finish last at the Leadville Marathon.

Dr. Joseph Antoun is the CEO and Chairman of the Board of L-Nutra, the leading fasting and fasting mimicking R&D and commercialization company. Dr. Antoun is also Chairman of the Board at the Global Healthspan Policy Institute (GHPI), Director of Health Policy at University of Chicago and fmr. Editor-in-Chief of The Journal of Health Systems Reform.

Dr. Antoun’s work focuses on enhancing Public Health and Human Healthspan through advancing technologies that promote healthy aging and advocating for health policy reforms that support R&D, regulatory processes and increasing access to innovative Healthspan technologies.

Dr. Antoun has completed his studies in Health Policy at Harvard University, in Public Health at Johns Hopkins University, and in Medicine and Biological Sciences at Saint Joseph University.

Barry Singer, M.D. is the director and founder of The MS Center for Innovations in Care, one of the largest comprehensive care multiple sclerosis centers in Midwest.  The center is on the campus of Missouri Baptist Medical Center in St. Louis.  Dr. Singer has been in the BJC Medical Group since 1999 and remains on staff at Barnes-Jewish Hospital in St. Louis where he practiced full-time from 1999 to 2008. He is an Associate Professor of Clinical Neurology at Washington University in St. Louis. Dr. Singer graduated college from Duke University in 1988 and medical school from Columbia University in 1992.  His neurology residency was at Cornell-New York Hospital and his two-year multiple sclerosis fellowship was at the National Institutes of Health.

Dr. Singer has been an investigator in more than 25 clinical trials focused on new multiple sclerosis treatment options since 1994. He continues to publish in the field of multiple sclerosis, present at global scientific meetings and serves as course director for national continuing medical education programs. As a leader in multiple sclerosis and patient advocate, he lectures on MS throughout the U.S. and globally.  In 2016, he was appointed to the Board of Directors of the Multiple Sclerosis Association of America and serves on the Executive Committee. He has also served on the health advisory committee of the Gateway Chapter of the National Multiple Sclerosis Society from 2000 to 2017 and is the recipient of the 2008 Pathlighter Award.  In addition, Dr. Singer has received a Congressional Proclamation for MS Research in 2008.

Suzanne Robotti is founder and president of MedShadow Foundation and serves on the  FDA Drug Safety and Risk Management Advisory Committee as the Consumer Representative. Su is also the Executive Director for DES Action USA.

• Two major health issues drove Su to become engaged in health and patient advocacy.
• Robotti’s mother, like millions of other women in the 1950s and 1960s, took the prescription drug DES (diethylstilbestrol), the world’s first endocrine disruptor (a synthetic estrogen). DES was given to women in pregnancy based on an inadequately tested theory that increasing estrogen levels in the body would prevent miscarriages and premature labor.
• The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer.
• DES was eventually taken off the market in 1971.
• When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure.
• Learning that she was infertile pushed her to join DES Action USA, a patient advocacy group.
• In 2010, her son’s physician prescribed Ritalin for his ADD, but was unable to explain the medication’s side effects. This prompted concern about the long-term effects of this stimulant on her son’s developing brain.
• These two personal experiences with side effects and long term effects of medicine prompted Robotti to form MedShadow Foundation as a means of bringing the issue of medication side effects into the public discourse.
• In 2015, DES Action USA joined MedShadow Foundation after 30+ years as one of the most effective grass roots education and advocacy groups ever. DES Action’s work continues as Robotti serves as executive director for the membership organization.

In addition to MedShadow, Robotti serves on the board of directors of New York City Community Board 7, the advisory board of Pace University’s Masters in Publishing program and is a trustee of Springfield College. Prior to founding MedShadow Foundation, she had a successful publishing industry career as founder first of Cradle Publishing and, later, Baby Publishing LLC which she later sold to Gruner+Jahr Bertelsmann.

She holds a Bachelor of Arts degree in Communications from the University of Maryland at College Park. Robotti has been honored for her extensive contributions to community service from The President’s Council on Service and Civic Participation.